A randomised, placebo-controlled phase 3 study to evaluate the efficacy and safety of ASP0113, a DNA-based CMV vaccine, in seropositive allogeneic haematopoietic cell transplant recipients.

Ljungman P, Bermudez A, Logan AC, Kharfan-Dabaja MA, Chevallier P, Martino R, Wulf G, Selleslag D, Kakihana K, Langston A, Lee DG, Solano C, Okamoto S, Smith LR, Boeckh M, Wingard JR, Cywin B, Fredericks C, Lademacher C, Wang X, Young J, Maertens J

Open source

DOI: 10.1016/j.eclinm.2021.100787
Published: 2021 Mar
Container: EClinicalMedicine
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.eclinm.2021.100787,
  title = {A randomised, placebo-controlled phase 3 study to evaluate the efficacy and safety of ASP0113, a DNA-based CMV vaccine, in seropositive allogeneic haematopoietic cell transplant recipients.},
  author = {Ljungman P and Bermudez A and Logan AC and Kharfan-Dabaja MA and Chevallier P and Martino R and Wulf G and Selleslag D and Kakihana K and Langston A and Lee DG and Solano C and Okamoto S and Smith LR and Boeckh M and Wingard JR and Cywin B and Fredericks C and Lademacher C and Wang X and Young J and Maertens J},
  year = {2021},
  journal = {EClinicalMedicine},
  doi = {10.1016/j.eclinm.2021.100787},
  url = {https://doi.org/10.1016/j.eclinm.2021.100787}
}

RIS

TY  - JOUR
TI  - A randomised, placebo-controlled phase 3 study to evaluate the efficacy and safety of ASP0113, a DNA-based CMV vaccine, in seropositive allogeneic haematopoietic cell transplant recipients.
AU  - Ljungman P
AU  - Bermudez A
AU  - Logan AC
AU  - Kharfan-Dabaja MA
AU  - Chevallier P
AU  - Martino R
AU  - Wulf G
AU  - Selleslag D
AU  - Kakihana K
AU  - Langston A
AU  - Lee DG
AU  - Solano C
AU  - Okamoto S
AU  - Smith LR
AU  - Boeckh M
AU  - Wingard JR
AU  - Cywin B
AU  - Fredericks C
AU  - Lademacher C
AU  - Wang X
AU  - Young J
AU  - Maertens J
PY  - 2021
JO  - EClinicalMedicine
DO  - 10.1016/j.eclinm.2021.100787
UR  - https://doi.org/10.1016/j.eclinm.2021.100787
ER  -

APA

P, L., A, B., AC, L., MA, K., P, C., R, M., G, W., D, S., K, K., A, L., DG, L., C, S., S, O., LR, S., M, B., JR, W., B, C., C, F., C, L., X, W., J, Y., & J, M. (2021). A randomised, placebo-controlled phase 3 study to evaluate the efficacy and safety of ASP0113, a DNA-based CMV vaccine, in seropositive allogeneic haematopoietic cell transplant recipients.. EClinicalMedicine. https://doi.org/10.1016/j.eclinm.2021.100787

Source records

pubmed · retrieved 2026-09-26T19:44:54.182Z